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We experienced a case of malignant hyperthermia (MH) in 6-year-old boy during anesthesia induction for strabismus 
surgery. It has been generally reported that sevoflurane can induce the delayed onset of MH in the absence of 
succinylcholine. Our case of MH was elicited after about 2-3 min of sevoflurane administration with N2O, O2 and 
rocuronium. However, we successfully treated the patient by early recognition of his condition and administering 
symptomatic treatment and dantrolene. (Korean J Anesthesiol 2010; 59: S6-S8)
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    Malignant hyperthermia (MH) is a chain reaction of 
symptoms that are triggered in susceptible individuals by 
commonly used inhalation agents such as halothane, enflurane, 
isoflurane and sevoflurane and also muscle relaxants such 
as succinylcholine. The symptoms of MH include a greatly 
increased body metabolism, high fever and muscle rigidity. 
It is known that sevoflurane and desflurane are less potent 
triggers that produce a more gradual onset of MH [1,2]. Yet we 
encountered a case of MH during anesthetic induction with 
sevoflurane, and the patient was successfully treated by early 
recognition of his condition and administering symptomatic 
treatment and dantrolene.
Case Report
    A 6-year-old, 25 kg boy was scheduled for strabismus surgery 
in both eyes. Neither the patient nor his family had any history 
of neuromuscular disease or a special family history. He had 
not previously received general anesthesia. The preoperative 
laboratory examinations were within the normal values. The 
patient received atropine 0.25 mg IM for premedication 30 
min before induction. The preoperative vital signs were blood 
pressure: 90/50 mmHg, heart rate: 92 beats/min, respiratory 
rate: 24/min and axillary temperature: 36.4
oC. The patient 
received ketamine 50 mg IV for sedation before induction in the S7 www.ekja.org
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waiting room.
    Anesthesia was induced with sevoflurane 2.5 vol% by mask 
ventilation in a mixture of nitrous oxide and oxygen (FiO2 
0.5). Fifteen mg of rocuronium bromide was injected during 
induction. About 2 min after injection of rocuronium bromide, 
a size 5.0 cuffed endotracheal tube was inserted without 
any difficulty under direct laryngoscopy. Then 1 min after 
intubation, the heart rate of patient was increased from 160 
to 195 beats/min. At first, the tachycardia was considered 
to be due to stimulation by the tracheal intubation, but 
the end tidal carbon dioxide concentration (ETCO2) was 
concurrently increased from 35 to 65 mmHg within 5 min. 
The oral temperature was increased to 38.9
oC within 5 min 
after induction. No significant changes in the muscle tone 
and skin appearance were noted. We suspected MH, so 
we stopped using sevoflurane and N2O. The patient was 
hyperventilated with 100% O2 through a new anesthetic circuit, 
and consequently the ETCO2 was decreased to 45 mmHg. The 
patient was administered midazolam 1 mg and sufentanyl 15 μg 
intravenously for sedation after discontinuing the sevoflurane 
and we started propofol infusion as maintenance because 
propofol is known to be a safe anesthetic agent in patients with 
MH. 
    For decreasing the body temperature, active cooling was 
immediately initiated by ice water massage and applying ice 
packs on the chest, back and axillary area. Arterial cannulation 
was done to continuously monitor the blood pressure and 
for the arterial blood gas analysis. This was done via external 
jugular cannulation for rapid infusion of cold IV fluid and 
central administration of drugs for resuscitation if it was need, 
and we placed a Foley catheter for checking the hour urine 
output. The arterial blood gas analysis was pH: 7.294, PaCO2: 
41.2 mmHg, PaO2: 435.2 mmHg and the base excess: -10.1 
mM/L. The myoglobin in the serum was normal and the urine 
was negative for myoglobin. The creatine phosphokinase and 
potassium levels in the serum were normal. We administered 
8.4% sodium bicarbonate 10 ml for correcting the acidosis. 
Thirty minutes min after anesthetic induction, the patient 
showed an oral temperature of 38
oC, a pulse of 160 beats/min, 
a blood pressure of 140/70 and we detected newly occurring 
ventricular premature beats (4-5/min) on the echocardiogram. 
So, we decided to stop the general anesthesia and surgery and 
administer dantrolene. But we didn’t have dantrolene, so we 
requested dantrolene from the Korea orphan drug center.
    Approximately 90 min after the onset of MH, the patient 
recovered consciousness and the tracheal tube was extubated. 
The patient was transferred to the intensive care unit for further 
observation. About 120 min after onset of MH, we received the 
dantrolene. The patient showed an oral temperature of 37.5
oC, 
a heart rate of 140 beats/min and a blood pressure of 140/80 
mmHg, and he maintained the ventricular premature beats 
(4-5/min). The arterial blood gas analysis showed a pH of 7.390, 
a PaCO2 of 38.0 mmHg, a PaO2 of 89.5 mmHg and a base excess 
of -2.5 mM/L.
    Dantrolene 25 mg was administered intravenously. Thereafter, 
the arrhythmia disappeared, and the patient maintained an oral 
temperature of 36.5-37.4
oC and a normal blood pressure and 
heart rate. But about 2 h after the administration of dantrolene, 
the patient again showed arrhythmia (ventricular premature 
beats) and an increased oral temperature of 38
oC, a blood 
pressure of 130/100 mmHg and a heart rate of 130 beats/min. 
Dantrolene 25 mg was administered again. After the second 
administration of dantrolene, the arrhythmia, oral temperature, 
heart rate and blood pressure were all normalized, and the 
laboratory data and arterial blood gas analysis were normalized 
2 days after anesthesia induction.
    Further evaluations for MH were refused by the patient’s 
parents. The patient was discharged from the hospital four days 
after the onset of MH without any problem.
Discussion
    Many early signs of a MH episode can present in various ways 
and MH may be confused with other medical conditions such 
as an insufficient depth of anesthesia, hypoxia, hypercarbia, 
thyrotoxicosis, pheochromocytoma and neuroleptic malignant 
syndrome [3,4]. A clinical grading scale helps to establish the 
likelihood of MH in specific problematic cases [5]. It is based on 
weighted scores for muscle tone, muscle breakdown, acid-base 
parameters, temperature, tachycardia or other arrhythmias, 
and the response to dantrolene. We were able to diagnose MH 
on the basis of the clinical symptoms and the clinical grading 
scale by Larach et al. [5]. According to this clinical grading 
scale, when the raw score range is 35-48, the MH rank is 5 
and the likelihood of MH is high. The patient in this case had 
a score of 43. The patient in this case received the score of 
43 because the PETCO2 was > 55 mmHg with appropriately 
controlled ventilation (15 points), there was an inappropriately 
rapid increase in temperature (15 points), inappropriate sinus 
tachycardia (3 points) and an arterial base excess more negative 
than -8 mEq/L (10 points). 
    In this case, we used ketamine, sevoflurane, N2O and rocuro-
nium bromide during induction. Ketamine and N2O are not 
triggers for MH [6-8] and rocuronium bromide, which is a non-
depolarizing muscle relaxant, is also safe for MH.
    Since Shulman et al. [1] first reported that sevoflurane triggers 
MH in MH-susceptible swine, there have been some reports 
of MH during sevoflurane anesthesia in human. Generally, 
sevoflurane and desflurane have been reported to be less potent 
triggers, they produce a more gradual onset of MH [1,2] and the S8 www.ekja.org
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onset of MH with sevoflurane in humans has been reported to 
occur both at an early period and after prolonged anesthesia. 
We encountered a case of MH that developed during anesthesia 
induction with sevoflurane. It took just about 5 minutes for 
eliciting the symptoms of MH. 
    Kinouchi et al. [9] reported MH emerged about 30 minutes 
after anesthetic induction with sevoflurane in 4-year-old girl 
who was without a family history of MH and the preoperative 
laboratory studies did not suggest she was susceptible to MH. 
Jonassen et al. [10] reported that MH emerged about 20 minutes 
after anesthetic induction with sevoflurane in a 56-year-old man 
who was undergoing cardiopulmonary bypass and moderate 
hypothermia. Cheong et al. [11] reported that MH emerged 
about 150 minutes after general anesthesia with sevoflurane in 
a 24-year-old man who was undergoing bilateral sagittal split 
ramus osteotomy. 
    As compared with the other case reports, our patient’s ETCO2 
and body temperature were increased simultaneously within 5 
minutes after anesthetic induction with sevoflurane. This is the 
earliest onset among the case reports of MH reported until now.
    We know that the time of onset of a fulminant episode of MH 
is unpredictable, and it can vary from within minutes to within 
several hours of induction, and the fulminant MH episodes are 
apparently the result of a rapid, sustained rise in myoplasmic 
Ca
2+. However, we could not determine the reason for the rapid 
onset of MH in this case.
    During the preoperative evaluation, our attention was drawn 
to the patient’ strabismus, and strabismus has been observed 
in MH susceptible patients. However, neither the family history 
nor the preoperative laboratory studies suggested the patient 
was susceptible to MH. There is no convenient minimally 
invasive laboratory test available for MH susceptibility. The 
halothane and caffeine contracture tests are bioassays and they 
currently remain the most reliable indicators, but they are not 
generally used in our country, and so a diagnostic contracture 
test was not performed.
    This case report demonstrates that sevoflurane can trigger 
MH within few minutes after exposure and so the patients who 
are susceptible to MH must be carefully monitored even during 
anesthetic induction.
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